Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis

Ann Atlas1,*, Elisabeth Franzen-Röhl1,*, Johan Söderlund4,*, Erik G Jönsson2, Martin Samuelsson3, Lilly Schwieler4, Birgit Sköldenberg1 and Göran Engberg4

1Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden. 2Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. 3Department of Clinical and Experimental Medicine, Division of Psychiatry, Linköping University, Linköping, Sweden. 4Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. *These authors contributed equally to this study.

ABSTRACT: Herpes simplex virus (HSV) type 1 encephalitis (HSE) is a viral infectious disease with commonly occurring neurodegeneration and neurological/cognitive long-term sequelae. Kynurenic acid (KYNA) is a neuroactive tryptophan metabolite, which is elevated in the cerebrospinal fluid (CSF) during viral infection as a result of immune activation. The aim of the study was to investigate the role of endogenous brain KYNA for the long-term outcome of the disease. CSF KYNA concentration was analyzed in 25 HSE patients along the course of the disease and compared with that of 25 age-matched healthy volunteers. Within 3 weeks of admission CSF KYNA of HSE patients was markedly elevated (median 33.6 nM) compared to healthy volunteers (median 1.45 nM). Following a decline observed after 1–2 months, levels of CSF KYNA were elevated more than 1 year after admission (median 3.4 nM range: 1–9 years). A negative correlation was found between initial CSF KYNA concentrations and severity of the long-term sequelae. This study show a marked elevation in CSF KYNA from patients with HSE, most pronounced during the acute phase of the disease and slowly declining along the recovery. We propose that brain KYNA might potentially protect against neurodegeneration while causing a long-lasting loss in cognitive function associated with the disease.

KEYWORDS: Tryptophan, NMDA hypofunction, HSE, neurodegeneration, cognition

Introduction

Herpes simplex virus (HSV) encephalitis (HSE) is the most frequent cause of sporadic necrotizing encephalitis in adults.1–3 Despite pharmacological treatment the associated mortality rate is still high, approximately 20% and permanent disability, particularly cognitive and memory impairment is common.4–6 The acute manifestation of HSE is not different from other encephalitis, and symptoms, ranging from mild to severe,7,8 include fever, headache, personality and behavioral changes, and focal neurological signs. Seizures during the acute stage are more common than in other encephalitis and occur in 33–67% of HSE patients.9–11 The long-term symptoms, occurring partly as a result of neurodegeneration12 varies from those seen at onset to non-febrile symptoms such as memory loss, cognitive deterioration and neurological/psychiatric manifestations (eg, depression, agony and sleeping disorder).9,13,14 Despite acyclovir treatment approximately 30–62% of the patients suffer from moderate to severe long-lasting sequelae, that affects both functioning and personality with pronounced impairment in quality of life.10,11,15 Neuropsychiatric sequelae are known to occur after HSE and the most common disabling symptom is cognitive dysfunction.4,16 The pathogenesis
of both HSE and the neuropsychiatric sequelae is unclear, both with regard to the primary infection and to the reactivation. There is no evidence that antibodies may protect against clinical manifestations of HSV and several studies have demonstrated that neutralizing specific antibodies do not provide protection against HSV infection or disease. Immune compromised patients with defects in cell mediated immunity experience more severe and more extensive HSV infections than those with deficits in humoral immunity. Increased knowledge of the mechanism behind the symptoms is crucial for improved treatment of the disease.

It is known that immune activation induces the kynurenine pathway of tryptophan degradation. This pathway is not only an important regulator of the innate and adaptive immune response but is also responsible for the biosynthesis of several neuroactive compounds. Kynurenic acid (KYNA) is an end-metabolite in one branch of this pathway. The compound is synthesized by astrocytes in the brain and acts as an antagonist at both the glycine site of the N-methyl-D-aspartate (NMDA) receptor and at the cholinergic α7 nicotine receptor. Apart from being neuroprotective and anticonvulsant, KYNA is also implicated in cognitive functions. Thus, elevated brain KYNA in rodents is associated with deficits in prepulse inhibition, spatial and contextual learning and memory, and impaired cognitive flexibility. Notably, elevated levels of KYNA have been detected in several diseases characterized by cognitive impairments, including psychiatric disorders such as schizophrenia and bipolar disorder.

In the present study, CSF KYNA was analyzed concomitant with symptom manifestation along the course of HSE, hereby enabling assessment of the role of the compound in the pathophysiology of the disease.

Materials and methods

Ethics. The work described in the present study was carried out in accordance with "The code of ethics of the world medical association (declaration of Helsinki) for experiments including humans: http://www.wma.net/en/30publications/10policies/b3/". The Ethical Committee on Human Investigations of the Faculty of Medicine, Karolinska Institutet, and the Regional Ethical Review Board in Stockholm approved the study. All participants provided written informed consent.

Subjects. KYNA was measured in CSF samples collected from 11 men and 14 women with herpes simplex type 1 encephalitis (Table 1). All patients in the study were retrospectively included and treated at the Department of Infectious Diseases at Danderyds Hospital, Stockholm from 1973–1996. CSF samples were obtained at enrollment, and all patients had clinical signs of encephalitis with CSF pleocytosis (≥5 × 10⁶ cells/L). 25 age-matched healthy volunteers, 11 men and 14 women, were used as controls (Table 2). Controls were free of medication for at least 1 month and free from any form of substance abuse. CSF levels of KYNA from these individuals have been previously published.

14 patients were diagnosed by the demonstration of HSV specific intrathecal antibody synthesis- indirect immunoassays by IgG in CSF and serum samples. 5 patients were diagnosed by demonstration of viral antigen in specimens obtained by brain biopsy. 1 patient was diagnosed by virus isolation from the throat and another by virus isolation from the CSF and 4 patients were diagnosed by IgM and IgG in sera. It was not possible to establish if the patients suffered from a primary or recurrent HSV infection due to lack of clinical history and diagnostic evidence. Co-infections with HSE and staphylococci septicemia were observed in 2 patients. One patient with HSE had alcohol abuse. 3 patients died during the first 3 weeks after admission, from lung edema, emboli of the heart and brain edema, respectively. Another patient died at day 54 after admission with brain edema. All patients were culture negative for bacteria and fungi in CSF. Demographic and clinical data were collected from medical records.

There are no specific clinical symptoms in HSE that differ from other encephalitides. During the acute onset of HSE, almost 100% of the patients presented fever, headache, personality and behavioral changes, including psychosis, and focal neurological signs (see Table 3). Half of the patients experience prodromal symptoms less than a week before onset of encephalitis symptoms. Patients in this study experienced symptoms of encephalitis for an average of 5 days before they were admitted to the hospital (mean 5 days, range 1–22 days). At enrollment all patients with HSE underwent a clinical examination and their symptoms were classified as “mild,” “moderate,” or “severe” encephalitis. The mild form was defined as a disease with predominantly meningeal symptoms, including fever, headache, rigidity of the neck, and nausea. The moderate form was defined as a disease with multifocal symptoms of the CNS and/or moderate diffuse brain dysfunction (in addition to symptoms seen in the mild form), whereas the severe form additionally included multifocal symptoms of the CNS and/or severe diffuse brain dysfunction.

The clinical outcome at long-term follow up was evaluated and graded as mild sequelae (minor impediment to activities of daily living), moderate sequelae (considerable impediment to activities of daily living), or severe sequelae (under institutional care).

Pharmacological treatment. All patients were given antiviral agents at admission: 11 patients were treated with acyclovir (10 mg/kg × 3 intravenously 10–14 days), 10 patients were treated with vidarabine (600–700 mg/day for 10 days), and 4 patients were treated with cytarabine (300 mg/day for 7 days). 19 patients received dexamethasone (4 mg × 4 for 3 days).

16 patients received phenytoin to prevent seizures, three of them received additional treatment with carbamazepine or diazepam.

Cerebrospinal fluid sampling. CSF samples were collected within 4 different time frames with regard to admission.
Kynurenic acid and herpes encephalitis

1) 0–3 weeks (n = 19), 2) 1–2 months (n = 9), 3) 6–12 months (n = 6), and 4) >1 year (n = 19). CSF was obtained by lumbar puncture (L4–L5) in a standardized manner. The lumbar punctures were performed with subjects in a lateral recumbent position. The third 1 mL portion of the CSF was frozen in 2 portions (0.5 mL each) at −25°C and was subsequently used for biochemical analysis. All CSF samples used in this study were collected between years 1973 and 1996.

Analysis of CSF KYNA. KYNA is a stable compound and is not degraded even by repeated thawing.44 We performed

---

**Table 1.** Demographic characteristics, baseline clinical, and laboratory findings for 25 patients with herpes simplex encephalitis.

| DIAGNOSIS | AGE AT ONSET | SEX | SYMPTOM CLASSIFICATION AT ONSET | KYNA 0–3 WEEKS | KYNA 1–2 MONTHS | KYNA 6–12 MONTHS | KYNA >1 YEAR | TREATMENT AT ADMISSION | ANTIEPILEPTIC TREATMENT | SEQUELAE CLASSIFICATION AFTER ONE YEAR |
|-----------|-------------|-----|-------------------------------|----------------|----------------|----------------|-------------|-------------------------|--------------------------|---------------------------------------|
| HSE*      | 17          | male | severe                        | 3.39           | –              | 1.11           | –           | acyclovir/dexamethasone | –                        | fully recovered                  |
| HSE       | 62          | male | moderate                      | 302.52         | –              | 8.57           | 8.35        | acyclovir               | phenytoin                | moderate                           |
| HSE       | 21          | female | moderate                   | –              | –              | 2.82           | 2.69        | cytarabine/dexamethasone | phenytoin                | moderate                           |
| HSE       | 35          | female | severe                       | 31.05          | 11.31         | –              | 10.67       | acyclovir               | phenytoin                | moderate                           |
| HSE       | 70          | male | moderate                      | 19.26          | 6.11           | –              | 5.72        | acyclovir/dexamethasone | –                        | n/a                                  |
| HSE       | 32          | female | moderate                   | –              | –              | –              | 3.61        | vidarabine/dexamethasone | –                        | n/a                                  |
| HSE       | 51          | male | moderate                      | 1.73           | 5.37           | –              | –           | acyclovir/dexamethasone | phenytoin                | n/a                                  |
| HSE       | 59          | female | n/a                          | –              | –              | –              | 3.18        | cytarabine/dexamethasone | –                        | moderate                           |
| HSE       | 61          | female | moderate                   | 26.44          | 11.06         | –              | 45.56       | acyclovir/dexamethasone | phenytoin, diazepam    | severe                               |
| HSE       | 71          | male | severe                        | 26.78          | 8.31           | –              | 1.59        | acyclovir/dexamethasone | phenytoin                | severe                               |
| HSE       | 27          | male | mild                          | 52.27          | 2.32           | 1.41           | –           | acyclovir/dexamethasone | –                        | n/a                                  |
| HSE       | 76          | male | moderate                      | 89.68          | 53.43         | –              | 4.21        | acyclovir               | –                        | n/a                                  |
| HSE       | 37          | female | severe                       | –              | –              | –              | 3.11        | cytarabine/dexamethasone | phenytoin, carbamazepine | moderate                           |
| HSE       | 35          | male | moderate                      | –              | –              | 1.22           | 1.54        | vidarabine               | –                        | severe                               |
| HSE       | 57          | male | moderate                      | 145.47         | 5.29           | –              | 1.25        | vidarabine/dexamethasone | phenytoin                | moderate                           |
| HSE       | 34          | female | severe                       | 46.05          | 10.61         | –              | 7.39        | cytarabine/dexamethasone | phenytoin                | n/a                                  |
| HSE       | 61          | male | severe                        | –              | –              | –              | 2.94        | vidarabine/dexamethasone | phenytoin                | severe                               |
| HSE       | 54          | female | severe                       | 6.67           | 1.98           | –              | 5.21        | acyclovir/dexamethasone | phenytoin                | severe                               |
| HSE       | 63          | female | moderate                   | 115.71         | 26.64         | –              | 5.34        | acyclovir/dexamethasone | phenytoin, carbamazepine | moderate                           |
| HSE       | 30          | female | moderate                   | 19.35          | –              | –              | 1.97        | vidarabine/dexamethasone | phenytoin                | severe                               |
| HSE       | 30          | male | mild                          | 98.07          | 13.07         | 3.76           | –           | vidarabine/dexamethasone | –                        | severe                               |
| HSE†      | 62          | female | severe                       | 71.66          | –              | –              | –           | vidarabine/dexamethasone | phenytoin                | n/a                                  |
| HSE†      | 75          | female | moderate                   | 51.56          | –              | –              | –           | vidarabine               | –                        | n/a                                  |
| HSE†      | 71          | female | severe                       | 22.07          | –              | –              | –           | vidarabine               | phenytoin                | n/a                                  |
| HSE†      | 16          | female | moderate                   | 33.63          | –              | –              | –           | vidarabine/dexamethasone | phenytoin                | n/a                                  |

*Patient almost fully recovered 3 weeks after admission.
†Patient died within 2 months after admission.
the analysis of KYNA using an isocratic reversed-phase high-performance liquid chromatography (HPLC) system, including a dual piston, high liquid delivery pump (Bischoff, Leonberg, Germany), a ReproSil-Pur C18 column (4 × 150 mm, Dr Maisch GmbH, Ammerbuch, Germany) and a fluorescence detector (Jasco Ltd, Hachioji City, Japan) with an excitation wavelength of 344 nm and an emission wavelength of 398 nm (18 nm bandwidth) essentially as previously described. A mobile phase of 50 mM sodium acetate pH 6.20 (adjusted with acetic acid) and 7.0% acetonitrile was pumped through the reversed-phase column at a flow rate of 0.5 mL/min. Samples (diluted in saline) of 30 µL were manually injected (Rheodyne, Rhonert Park, CA, USA). Zinc acetate (0.5 M, not pH adjusted) was delivered after the column by a peristaltic pump (P-500, Pharmacia, Uppsala, Sweden) at a flow rate of 10 mL/h. Signals from the fluorescence detector were transferred to a computer for analysis with Datalys Azur (version 4.6.0.0;http://datalys.net). The retention time of KYNA was about 7 min. The sensitivity of the system was verified by analysis of standard mixture of KYNA with concentrations from 0.5–30 nM, which resulted in a linear standard plot. The samples were analyzed in singles. Some samples were analyzed in duplicates, and the intra-individual variation was less than 5%.

**Statistical analysis.** Results are presented as medians and inter-quartile range (P25–P75). The Mann-Whitney U test was used to analyze group differences regarding CSF levels of KYNA and Spearman rank order correlation coefficient was used to measure the association between KYNA levels and age. P < 0.05 was considered statistically significant.

**Results**

Analysis of CSF from age- and gender matched healthy volunteers show KYNA levels within a narrow concentration span at the same magnitude as those previously found in healthy volunteers (Table 2). CSF KYNA of HSE patients, obtained within 3 weeks of admission, was significantly elevated (median 33.6 nM (19.4–89.7), n = 19; Fig. 1) compared to healthy volunteers (median 1.45 nM (1.23–2.46), n = 25, P < 0.0001). The variation in CSF KYNA concentration in HSE patients within this time interval was very large, with a minimum and maximum value of 1.73 and 302 nM, respectively (Fig. 1). The initially high concentration of CSF KYNA progressively declined within 2 months. However, levels of CSF KYNA were significantly elevated more than 1 year after admission (median 3.40 (1.69–5.63), n = 18, range: 1–9 years; P < 0.0013) compared to healthy volunteers (Fig. 1).

No significant differences in CSF KYNA levels were observed, at any time period, between patients that were subdivided into groups based on symptom severity at admission (Fig. 1). However, long-term symptoms were found to be associated with initial levels of CSF KYNA at admission. Thus, patients with severe sequelae (n = 5) displayed lower levels of CSF KYNA within 3 weeks at admission compared to the group of moderate sequelae (n = 4; Fig. 2).

Notably, 1 subject with staphylococci septicemia during admission displayed the highest detected level of CSF KYNA compared to other patients. We could not find any differences in CSF KYNA levels between genders neither within 3 weeks after admission (female median 32.2 nM (21.4–56.6), n = 10; male median 52.3 nM (11.3–121), n = 9, P = 0.66), nor at any other point of time. Furthermore, KYNA levels did not associate with consciousness or seizures (results not shown).

**Discussion**

The present longitudinal study allows an estimation of CSF KYNA in HSE patients along the course of infection. Our results show that CSF KYNA varies along different stages of the disease and that very high CSF levels, compared to healthy volunteers, are observed during the first 3 weeks of infections. Although CSF KYNA levels started to decline in most HSE patients after 1 to 2 months, levels were still significantly above those of healthy controls more than 1 year after admission.

The activity of the kynurenine pathway is critically regulated by the rate-limiting enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan-dioxygenase (TDO). One of these enzymes, IDO, is potently induced by pro-inflammatory infections. Although CSF KYNA levels started to decline in most HSE patients after 1 to 2 months, levels were still significantly above those of healthy controls more than 1 year after admission.
cytokines like interferon (IFN)-γ. In this context, previous studies have shown a significant elevation in CSF IFN-γ in patients with HSE. Notably, HSE in mice is associated with an increased activity of IDO in the spinal cord. Thus, the presently observed elevation of CSF KYNA in patients with HSE may be causally related to an activation of cytokines; e.g., an excess of brain IFN-γ, that subsequently induces IDO of the kynurenine pathway.

The significance of a facilitated tryptophan degradation via the kynurenine pathway as a result of an immune activation is unclear and it is a challenging question whether activation of the kynurenine pathway is forcing up the malignity of an infection, or alternatively, serves to dampen infections and prevent its consequences in terms of neuroprotection. The break-down of tryptophan by the kynurenine pathway generates several metabolites that in a complex manner modify the responsiveness of the immune system to inflammation and infection. Thus, a decreased availability of tryptophan, e.g., as a result of increased activity of the kynurenine pathway, may serve as a defense mechanism of the host by reducing the local supply of this essential amino acid to intracellular pathogens. However, several metabolites of the kynurenine pathway display immunotolerant properties, including a reduction in pro-inflammatory T cells (Th1, Th17) or enhancement of anti-inflammatory T cells. In particular, IDO activation and the production of downstream kynurenine metabolites is associated with development regulatory T cells, which may restrict an ongoing specific antiviral immune response. Likewise, the inhibition of IDO may thus improve the efficiency of a cytotoxic T cells response in HIV-1 encephalitis. Yet, with regard to the presently observed activation of the kynurenine pathway in HSE, the detailed immunological significance remains obscure.

KYNA may also directly affect neurodegeneration, which is frequently seen in HSE. Several metabolites of the kynurenine pathway, including KYNA and quinolinic acid, are neuroactive, blocking and stimulating the glutamatergic NMDA receptor, respectively. The neuroprotective action of KYNA is well described, and with regard to HSE, such an effect would principally serve to counteract neurodegeneration. In the present study, we found a correlation between clinical outcome in the long-term follow up and levels of CSF KYNA at admission. Thus, patients with a moderate sequelae as observed in follow up (see Methods) showed significantly higher CSF KYNA at admission compared to patients with a severe sequelae. This finding is the first to offer clinical support for a neuroprotective effect of endogenous KYNA in a condition of brain inflammation. In contrast to KYNA, quinolinic acid displays neurotoxic and convulsive properties. This relatively weak NMDA-receptor agonist is shown to be increased in the spinal cord of HSV-1 infected mice with encephalitis. However, in the presence of elevated levels endogenous KYNA, the neurotoxic actions of quinolinic acid would be less pronounced. Indeed, KYNA has previously been shown to critically control the vulnerability of mice brain striatal neurons to quinolinic acid.

A large body of previous studies implicates brain KYNA in psychotic disorders. The results of the present study strongly support this view; although many patients had alterations in consciousness at admission that may have masked psychiatric symptoms, psychotic behavior was commonly seen in line with observations of Whitley. Brain KYNA is also suggested to account for the cognitive deficits seen following other brain infections, such as HIV-1 encephalitis, or tick-borne encephalitis (TBE). A majority of the surviving HSE patients develop chronic cognitive deficits, probably related to the loss of tissue in the temporal lobes. Numerous studies show an intimate relation between glutamatergic/cholinergic activity and cognitive functions. In consonance, increased levels of brain KYNA have recently been shown to impair spatial working memory and cognitive flexibility in the rat. Similarly, a reduction in endogenous KYNA enhances cognitive behavior. The elevated levels of KYNA observed in the present study may thus relate to psychotic symptoms during the acute phase and may partly account for the long-term cognitive deficits of the disease. Altogether, KYNA may paradoxically affect cognition in HSE patients in 2 opposite ways; the neuroprotective action of the compound during the acute phase of the disease may serve to prevent for general long-term sequelae, whereas chronic elevation of the compound after infection recovery may generate persistent cognitive disabilities.

A confound of the present study is the medication of the HSE patients. In order to minimize brain swelling and epileptic seizures most patients received dexamethasone and/or phenytoin, drugs interfering directly with the enzymes regulating the formation of KYNA. Glucocorticoids stimulate the activity of the IDO/TDO and anti-epileptic drugs like phenytoin or carbamazepine have been shown to augment...
the activity of kynurenine aminotransferase (KAT) thereby increasing the synthesis of brain KYNA. However, since dexamethasone treatment only lasted for 3 days in the majority of patients and the biological activity in the tissues is estimated to last another 2 days, the impact on KYNA levels after the first week may be limited. Moreover, there was no statistical difference in KYNA levels between HSE patients receiving phenytoin and those who did not. The information on how long the patients received phenytoin is lacking, but there was no statistical difference with regard to KYNA levels between patients that received phenytoin and those who did not. All patients received acyclovir and the incorporation of defective thymidine residues into the viral genome utilizing viral thymidine kinase is a well established mechanism to reduce herpes virus replication. Although few serious side effects have been reported for acyclovir, this drug has also been suggested to inhibit IDO/TDO in rat brain. If anything, such an effect of acyclovir should reduce the formation of KYNA. Taken together, a pharmacological contribution to the changes in kynurenic acid levels cannot be fully excluded, in particular a contribution of phenytoin to the early increase in CSF KYNA.

In summary, the results of the present study describe a marked elevation in CSF KYNA from patients with HSE, most pronounced during the acute phase of the disease and generally declining along the recovery. With regard to severe encephalitis, brain KYNA may serve as a double-edged sword, showing an important neuroprotective action preferentially during the acute phase of the disease, along with a long-term cognitive impairment most visible during and after recovery.

**Author Contributions**

Conceived and designed the experiments: AA, EF, BS. Analyzed the data: AA, EF, JS, LS. Wrote the first draft of the manuscript: AA, EF, JS. Contributed to the writing of the manuscript: GE, LS, EJ, MS. Agree with manuscript results and conclusions: AA, EF, JS, EJ, MS, LS, BS, GE. Jointly developed the structure and arguments for the paper: AA, EF, JS, LS, GE. Made critical revisions and approved final version: AA, EF, JS, EJ, MS, LS, BS, GE. All authors reviewed and approved of the final manuscript.

**DISCLOSURES AND ETHICS**

As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

**REFERENCES**

1. Sköldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl. 1991;80:40–6.
2. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513–8.
3. Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret’s. Herpes. 2004;11 Suppl 2:57 A–64 A.
4. Sköldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl. 1996;100:8–13.
5. Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis. 2005;16(1):17–23.
6. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006;71(2–3):141–8.
7. Whitley RJ, Soong SJ, Lineman C Jr, Liu C, Pavia G, Alford CA. Herpes Simplex Encephalitis. Clin Asstment. JAMA. 1982;247:317–20.
8. Kohl S. Herpes simplex virus encephalitis in children. Pediatr Clin North Am. 1988;35(3):465–83.
9. Sköldenberg B, Forsgren M, Alesvig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984;2(8405):707–11.
10. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314(3):144–9.
11. Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002;35(3):254–60.
12. Damasio AR, Van Hoesen GW. The limbic system and the localisation of herpes simplex encephalitis. J Neurol Neurosurg Psychiatry 1985;48(4):297–301.

13. Gordon B, Selnes OA, Hart J, Hanley DF, Whitley RJ. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol 1981;38(8):466–7.

14. McGrath N, Anderson NE, Croxson MC, Powell KE. Herpes simplex encephalitis treated with acyclovir. diagnosis and long term outcome. J Neurol Neurosurg Psychiatry 1997;63:321–6.

15. Domingues RB, Tsimacis AM, Panutti CS, Mayo MS, Lakeman FD. Evaluation of the range of clinical presentations of herpes simplex encephalitis by using polymerase chain reaction assay of cerebrospinal fluid samples. Clin Infect Dis. 1997;25(1):86–91.

16. Hjalmarsson A, Blomqvist P, Kölschberg B. Herpes simplex encephalitis in Sweden, 1990–2001: incidence, morbidity, and mortality. Clin Infect Dis. 2003;37(4):785–80.

17. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

18. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

19. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

20. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

21. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

22. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

23. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

24. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

25. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

26. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

27. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

28. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

29. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

30. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

31. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

32. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

33. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

34. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

35. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

36. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

37. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

38. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

39. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

40. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

41. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

42. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

43. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

44. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

45. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

46. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

47. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

48. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

49. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

50. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.

51. Conley ME, Broides A, Hernande–Trujillo V, et al. Genetic analysis of patients with onset of early B-cell development. Immunol Rev 2005;206:213–36.
67. Kocki T, Wielosz M, Turski WA, Urbanska EM. Enhancement of brain kynurenic acid production by anticonvulsants—novel mechanism of antiepileptic activity? *Eur J Pharmacol*. 2006;541(3):147–51.

68. Müller AC, Dairam A, Limson JL, Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. *Life Sci.* 2007;80(10):918–25.

69. Müller C, Daya S. Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels. *Metab Brain Dis.* 2008;23:351–60.